Associated Papers
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.
Rose AAN et al.
Nature Communications, 2026
41484121 (PubMed )
Supplement: 41467_2025_68076_MOESM1_ESM.pdf
Real-World Evidence of the Prevalence of Driver Mutations in Anorectal Melanoma.
Jutten E et al.
Molecular Diagnosis & Therapy, 2025
Molecular Characterization of Advanced-Stage Melanomas in Clinical Practice Using a Laboratory-Developed Next-Generation Sequencing Panel.
Maloberti T et al.
Diagnostics (basel, Switzerland), 2024
38667446 (PubMed )
Supplement: diagnostics-14-00800-s001.zip › Supplementary_Table_S1.xlsx › Foglio1
The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers.
Kazandjian S et al.
Cancers, 2024
38275886 (PubMed )
Supplement: cancers-16-00445-s001.zip › Supplementary_Tables_S1-S18.xlsx › S1_Incidence_BRAF_Alterations
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB et al.
Esmo Open, 2023
37922692 (PubMed )
Supplement: mmc1.docx
Pan-Genomic Sequencing Reveals Actionable CDKN2A/2B Deletions and Kataegis in Anaplastic Thyroid Carcinoma.
Stenman A et al.
Cancers, 2021
Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: A valuable model for studying the impact of genetic diversity in melanoma.
Tran KB et al.
Pigment Cell & Melanoma Research, 2021
Multidisciplinary Care for Melanoma of Unknown Primary: Experience in the Era of Molecular Profiling.
De Andrade JP et al.
Annals of Surgical Oncology, 2020
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours.
Griewank KG et al.
British Journal of Cancer, 2013
23799844 (PubMed )
Supplement: bjc2013312x2.doc
Select a paper to view details